Cyclin-dependent protein kinases as therapeutic targets in cardiovascular disease

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 5, 2003, Pages 579-588

  Edo, María Dolores ^a   Roldán, Marta ^a   Andrés, Vicente ^a  

^a INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

Author keywords

Cardiovascular disease; Cyclin; Cyclin dependent kinase (inhibitor); Gene therapy; Pharmacological therapy

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; 2 BIS(2 HYDROXYETHYL)AMINO 9 ISOPROPYL 6 (4 METHOXYBENZYLAMINO)PURINE; ADENOSINE TRIPHOSPHATE; ALKALOID DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; CYCLIN B1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; FLAVONOID; FLAVOPIRIDOL; INDAZOLE DERIVATIVE; INDIRUBIN; OXINDOLE; PAULLONE DERIVATIVE; PROTEIN P19; PROTEIN P21; PROTEIN P27; PTERIDINE DERIVATIVE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; RIBOZYME; SEMICARBAZIDE DERIVATIVE; STAUROSPORINE;

ARTERY INTIMA; ATHEROSCLEROSIS; BINDING SITE; BONE MARROW TRANSPLANTATION; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME SUBUNIT; GENE THERAPY; GRAFT FAILURE; GROWTH STIMULATION; HUMAN; MEDICAL DOCUMENTATION; NONHUMAN; PATENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTEIN EXPRESSION; PROTEIN FAMILY; RESTENOSIS; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0038446704     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.5.579     Document Type: Review

References (83)

1. ROSS R: Atherosclerosis: an inflammatory disease. N. Engl. J. Med. (1999) 340:115-126.
2. STEINBERG D: Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat. Med. (2002) 8:1211-1217.
3. SHIMIZU K, SUGIYAMA S, AIKAWA M et al.: Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy. Nat. Med. (2001) 7:738-741.
4. RELIGA P BOJAKOWSKI K, MAKSYMOWICZ M et al.: Smooth-muscle progenitor cells of bone marrow origin contribute to the development of neointimal thickenings in rat aortic allografts and injured rat carotid arteries. Transplantation (2002) 74:1310-1315.
5. SATA M, SAIURA A, KUNISATO A et al.: Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat. Med. (2002) 8:403-409.
6. SARTORE S, CHIAVEGATO A, FAGGIN E et al.: Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ. Res. (2001) 89:1111-1121.
7. DZAU VJ, BRAUN-DULLAEUS RC, SEDDING DG: Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. (2002) 8:1249-1256.
8. CORTÉS MJ, DÍEZ-JUAN A, PÉREZ P et al.: Increased early atherogenesis in young versus old hypercholesterolemic rabbits by a mechanism independent of arterial cell proliferation. FEBS Lett. (2002) 522:99-103.
9. Kip1 protects against diet-induced atherosclerosis. FASEB J. (2001) 15:1989-1995.
10. ROSS R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 362:801-809.
11. 3H autoradiography. Circ. Res. (1962) 11:329-336.
12. MCMILLAN GC, STARY HC: Preliminary experience with mitotic activity of cellular elements in the atherosclerotic plaques of cholesterol-fed rabbits studied by labeling with tritiated thymidine. Ann. NY Acad. Sci. (1968) 149:699-709.
13. ROSENFELD ME, ROSS R: Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis (1990) 10:680-687.
14. BAUTERS C, ISNER JM: The biology of restenosis. Prog. Cardiovasc. Dis. (1997) 40:107-116.
15. ANDRÉS V: Control of vascular smooth muscle cell growth and its implication in atherosclerosis and restenosis. Int. J. Molec. Med. (1998) 2:81-89.
16. LIBBY P, TANAKA H: The molecular basis of restenosis. Prog. Cardiovasc. Dis. (1997) 40:97-106.
17. BURRIG KF: The endothelium of advanced arteriosclerotic plaques in humans. Arterioscler. Thromb. (1991) 11:1678-1689.
18. GORDON D, REIDY MA, BENDITT EP, SCHWARTZ SM: Cell proliferation in human coronary arteries Proc. Natl. Acad. Sci. USA (1990) 87:4600-4604.
19. KATSUDA S, COLTRERA MD, ROSS R, GOWN AM: Human atherosclerosis. IV. Immunocytochemical analysis of cell activation and proliferation in lesions of young adults. Am. J. Pathol (1993) 142:1787-1793.
20. KEARNEY M, PIECZEK A, HALEY L et al.: Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation (1997) 95:1998-2002.
21. O'BRIEN ER, ALPERS CE, STEWART DK et al.: Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy. Circ. Res. (1993) 73:223-231.
22. OREKHOV AN, ANDREEVA ER, MIKHAILOVA IA, GORDON D: Cell proliferation in normal and atherosclerotic human aorta: proliferative splash in lipid-rich lesions. Atherosclerosis (1998) 139:41-48.
23. REKHTER MD, GORDON D: Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques. Am. J. Pathol. (1995) 147:668-677.
24. TANNER FC, YANG Z-Y, DUCKERS E et al.: Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ. Res. (1998) 82:396-403.
25. VEINOT JP, MA X, JELLEY J, O'BRIEN ER: Preliminary clinical experience with the pullback atherectomy catheter and the study of proliferation in coronary plaques. Can. J. Cardiol. (1998) 14:1457-1463.
26. WEI GL, KRASINSKI K, KEARNEY M et al.: Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ. Res. (1997) 80:418-426.
27. ESSED CE, VAN DEN BRAND M, BECKER AE: Transluminal coronary angioplasty and early restenosis. Fibrocellular occlusion after wall laceration. Br. Heart J. (1983) 49:393-396.
28. NOBUYOSHI M, KIMURA T, OHISHI H et al.: Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J. Am. Coll. Cardiol. (1991) 17:433-439.
29. O'BRIEN ER, URIELI-SHOVAL S, GARVIN MR et al.: Replication in restenotic atherectomy tissue. Atherosclerosis (2000) 152:117-126.
30. PICKERING JG, WEIR L, JEKANOWSKI J, KEARNEY MA, ISNER JM: Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J. Clin. Invest. (1993) 91:1469-1480.
31. ISNER JM: Vascular remodeling. Honey, I think I shrunk the artery. Circulation (1994) 89:2937-2941.
32. SAKAI M, KOBORI S, MIYAZAKI A, HORIUCHI S: Macrophage proliferation in atherosclerosis. Curr. Opin. Lipidol. (2000) 11:503-509.
33. DARTSCH PC, VOISARD R, BAURIEDEL G, HOFLING B, BETZ E: Growth characteristics and cytoskeletal organization of cultured smooth muscle cells from human primary stenosing and restenosing lesions. Arteriosclerosis (1990) 10:62-75.
34. MORGAN DO: Principles of CDK regulation. Nature (1995) 374:131-134.
35. STEVAUX O, DYSON NJ: A revised picture of the E2F transcriptional network and RB function. Curr. Opin. Cell. Biol. (2002) 14:684-691.
36. Kip1: regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp. Cell. Res. (2001) 264:148-168.
37. BRAUN-DULLAEUS RC, MANN MJ, SEAY U et al.: Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler. Thromb. Vasc. Biol. (2001) 21:1152-1158.
38. ABE J, ZHOU W, TAGUCHI J et al.: Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem. Biophys. Res. Commun. (1994) 198:16-24.
39. Kip1 and cyclin E in human atherosclerotic tissue: implications for lesion cellularity. Atherosclerosis (1999) 144:7-14.
40. ANDRÉS V, CASTRO C: Antiproliferative strategies for the treatment of vascular proliferative disease. Curr. Vasc. Pharmacol. (2003) 1:85-98.
41. FISCHER PM: Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Curr. Opin. Drug Discov. Dev. (2001) 4:623-634.
42. IVORRA C, SAMYN H, EDO MD et al.: Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease. Curr. Pharm. Biotech. (2003) 4:21-37.
43. BROOKS EE, GRAY NS, JOLY A et al.: CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. (1997) 272:29207-29211.
44. RUEF J, MESHEL AS, HU Z et al.: Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation in vivo after carotid injury in the rat. Circulation (1999) 100:659-665.
45. MORISHITA R, GIBBONS GH, ELLISON KE et al.: Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides. J. Clin. Invest. (1994) 93:1458-1464.
46. MORISHITA R, GIBBONS GH, KANEDA Y, OGIHARA T, DZAU VJ: Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene (1994) 149:13-19.
47. MORISHITA R, GIBBONS GH, ELLISON KE et al.: Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA (1993) 90:8474-8478.
48. ROBINSON KA, CHRONOS NA, SCHIEFFER E et al.: Endoluminal local delivery of PCNA/cdc2 antisense oligonucleotides by porous balloon catheter does not affect neointima formation or vessel size in the pig coronary artery model of postangioplasty restenosis. Cathet. Cardiovasc. Diagn. (1997) 41:348-353.
49. ZHU NL, WU L, LIU PX et al.: Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation (1997) 96:628-635.
50. SUZUKI J-I, ISOBE M, MORISHITA R et al.: Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat. Med. (1997) 3:900-903.
51. MANN M, GIBBONS GH, KERNOFF RS et al.: Genetic engineering of vein grafts resistant to atherosclerosis. Proc. Natl. Acad. Sci. USA (1995) 92:4502-4506.
52. HU WY, FUKUDA N, NAKAYAMA M, KISHIOKA H, KANMATSUSE K: Inhibition of vascular smooth muscle cell proliferation by DNA-RNA chimeric hammerhead ribozyme targeting to rat platelet-derived growth factor A-chain mRNA. J. Hypertens. (2001) 19:203-212.
53. HU WY, FUKUDA N, KISHIOKA H et al.: Hammerhead ribozyme targeting human platelet-derived growth factor A-chain mRNA inhibited the proliferation of human vascular smooth muscle cells. Atherosclerosis (2001) 158:321-329.
54. FRIMERMAN A, WELCH PJ, JIN X et al.: Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation (1999) 99:697-703.
55. YAMAMOTO K, MORISHITA R, TOMITA N et al.: Ribozyme oligonucleotides against transforming growth factor-β inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. Circulation (2000) 102:1308-1314.
56. Kip1, an inhibitor of neointima formation in the rat carotid artery. J. Clin. Invest. (1997) 99:2334-2341.
57. Kip1 in angiotensin II-stimulated vascular smooth muscle cell hypertrophy. J. Clin. Invest. (1999) 104:815-823.
58. Kip1 expression by mitogenic and hypertrophic factors: involvement of transcriptional and posttranscriptional mechanisms. J. Cell. Biol. (2000) 148:543-556.
59. CHEN D, WALSH K, WANG J: Regulation of cdk2 activity in endothelial cells that are inhibited from growth by cell contact. Arterioscler. Thromb. Vasc. Biol. (2000) 20:629-635.
60. Kip1 by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis. FASEB J. (2001) 15:1877-1885.
61. KOYAMA H, RAINES EW, BORNFELDT KE, ROBERTS JM, ROSS R: Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of cdk2 inhibitors. Cell (1996) 87:1069-1078.
62. Kip1, in rat hearts during development. J. Mol. Cell. Cardiol. (1998) 30:463-474.
63. Kip1 knockout mice. Circ. Res. (1999) 85:117-127.
64. ROQUE M, REIS ED, CORDON-CARDO C et al.: Effect of p27 deficiency and rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model. Lab. Invest. (2001) 81:895-903.
65. CHAMLEY-CAMPBELL JH, CAMPBELL GR, ROSS R: Phenotype-dependent response of cultured aortic smooth muscle to serum mitogens. J. Cell Biol. (1981) 89:379-383.
66. MAJACK RA, GRIESHABER NA, COOK CL et al.: Smooth muscle cells isolated from the neointima after vascular injury exhibit altered responses to platelet-derived growth factor and other stimuli. J. Cell Physiol. (1996) 167:106-112.
67. BOCHATON-PIALLAT ML, ROPRAZ P, GABBIANI F, GABBIANI G: Phenotypic heterogeneity of rat arterial smooth muscle cell clones. Implications for the development of experimental intimal thickening. Arterioscler. Thromb. Vasc. Biol. (1996) 16:815-820.
68. TOPOUZIS S, MAJESKY MW: Smooth muscle lineage diversity in the chick embryo. Two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factor-β. Dev. Biol. (1996) 178:430-445.
69. LI S, FAN YS, CHOW LH et al.: Innate diversity of adult human arterial smooth muscle cells: cloning of distinct subtypes from the internal thoracic artery. Circ. Res. (2001) 89:517-525.
70. YANG Z, OEMAR BS, CARREL T et al.: Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors. Circulation (1998) 97:181-187.
71. OLSON NE, KOZLOWSKI J, REIDY MA: Proliferation of intimal smooth muscle cells. Attenuation of basic fibroblast growth factor 2-stimulated proliferation is associated with increased expression of cell cycle inhibitors. J. Biol. Chem. (2000) 275:11270-11277.
72. Kip1 in smooth muscle cells from different vascular beds. A potential role in establishing regional phenotypic variance. J. Biol. Chem. (2003) 278:4482-4490.
73. IHLING C, MENZEL G, WELLENS E et al.: Topographical association between the cyclin-dependent kinases inhibitor p21, p53 accumulation, and cellular proliferation in human atherosclerotic tissue. Arterioscler. Thromb. Vasc. Biol. (1997) 17:2218-2224.
74. CHANG MW, BARR E, LU MM, BARTON K, LEIDEN JM: Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest. (1995) 96:2260-2268.
75. UENO H, MASUDA S, SNISHIO S et al: Adenovirus-mediated transfer of cyclin-dependent kinase inhibitor p21 suppresses neointimal formation in the balloon-injured rat carotid arteries in vivo. Ann. NY Acad. Sci. (1997) 811:401-411.
76. YANG Z-Y, SIMARI RD, PERKINS ND et al.: Role of p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc. Natl. Acad. Sci. USA (1996) 93:7905-7910.
77. CONDORELLI G, AYCOCK JK, FRATI G, NAPOLI C: Mutated p21/WAF/CIP transgene overexpression reduces smooth muscle cell proliferation, macrophage deposition, oxidation-sensitive mechanisms, and restenosis in hypercholesterolemic apolipoprotein E knockout mice. FASEB J. (2001) 15:2162-2170.
78. Ink4 on vascular smooth muscle cell proliferation. Circulation (2000) 101:2022-2025.
79. BAI H, MORISHITA R, KIDA I et al.: Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene. Gene Ther. (1998) 5:761-769.
80. CALIFF RM, FORTIN DF, FRID DJ et al.: Restenosis after coronary angioplasty: an overview. J. Am. Coll. Cardiol. (1991) 17:2B-13B.
81. CHAN AW, CHEW DP, LINCOFF AM: Update on pharmacology for restenosis. Curr. Interv. Cardiol. Rep. (2001) 3:149-155.
82. FRANKLIN SM, FAXON DP: Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. Coronary Artery Dis. (1993) 4:232-242.
83. POPMA JJ, CALIFF RM, TOPOL EJ: Clinical trials of restenosis after coronary angioplasty. Circulation (1991) 84:1426-1436.